Transplantation möjlighet vid kolorektala levermetastaser
(2020) In Läkartidningen 17-18.- Abstract (Swedish)
- Surgical treatment of liver metastases from colorectal cancer (CLM) is the only treatment option with curative potential; however, only about 15% to 20% of the patients seen at major hospitals are candidates for surgical resection. In a prospective study of liver transplantation (Ltx) for non-resectable CLM a 5-year overall survival rate of 60 % has been shown. We now plan to evaluate if the addition of Ltx to conventional treatment of non-resectable, non-ablatable CLM increases overall survival compared to best established treatment. This will be done in a randomized study, primarily utilizing liver grafts from extended criteria donors not utilized for approved indications.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/94b356f1-b290-4534-965c-09717ba808d5
- author
- Lindnér, Per
; Hagman, Helga
LU
and Söderdahl, Gunnar
- publishing date
- 2020-04-20
- type
- Contribution to journal
- publication status
- published
- in
- Läkartidningen
- volume
- 17-18
- publisher
- Swedish Medical Association
- ISSN
- 0023-7205
- language
- Swedish
- LU publication?
- no
- additional info
- PMID: 32314327
- id
- 94b356f1-b290-4534-965c-09717ba808d5
- alternative location
- https://lakartidningen.se/klinik-och-vetenskap-1/kommentar/2020/04/transplantation-mojlighet-vid-kolorektala-levermetastaser/
- date added to LUP
- 2025-06-24 11:42:06
- date last changed
- 2025-06-24 13:03:35
@misc{94b356f1-b290-4534-965c-09717ba808d5,
abstract = {{Surgical treatment of liver metastases from colorectal cancer (CLM) is the only treatment option with curative potential; however, only about 15% to 20% of the patients seen at major hospitals are candidates for surgical resection. In a prospective study of liver transplantation (Ltx) for non-resectable CLM a 5-year overall survival rate of 60 % has been shown. We now plan to evaluate if the addition of Ltx to conventional treatment of non-resectable, non-ablatable CLM increases overall survival compared to best established treatment. This will be done in a randomized study, primarily utilizing liver grafts from extended criteria donors not utilized for approved indications.}},
author = {{Lindnér, Per and Hagman, Helga and Söderdahl, Gunnar}},
issn = {{0023-7205}},
language = {{swe}},
month = {{04}},
publisher = {{Swedish Medical Association}},
series = {{Läkartidningen}},
title = {{Transplantation möjlighet vid kolorektala levermetastaser}},
url = {{https://lakartidningen.se/klinik-och-vetenskap-1/kommentar/2020/04/transplantation-mojlighet-vid-kolorektala-levermetastaser/}},
volume = {{17-18}},
year = {{2020}},
}